Monograph Details
|
|
Neoplasms
> Hormones and antagonists
|
|
AROMASIN |
| Manufacturer |
|
Pfizer Labs |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Aromatase inactivator. |
| Generic Name |
|
Exemestane 25mg; tabs. |
| Indications |
|
In postmenopausal women: adjuvant treatment of estrogen-receptor positive early breast cancer after 2–3 years of tamoxifen therapy to complete a total of 5 years of hormonal therapy; advanced breast cancer with disease progression after tamoxifen therapy. |
| Children |
|
Not applicable. |
| Adults |
|
Give after a meal. 25mg once daily. Concomitant potent CYP3A4 inducer (eg, rifampicin, phenytoin): 50mg once daily. Advanced disease: continue until tumor progression is evident. |
| Contraindications |
|
Pregnancy (Cat.D). |
| Precautions |
|
Not for premenopausal women. Hepatic or renal insufficiency. Nursing mothers. |
| Interactions |
|
May be antagonized by estrogens (avoid), CYP3A4 inducers. |
| Adverse Reactions |
|
Fatigue, nausea, GI upset, hot flashes, arthralgia, pain, increased appetite, increased sweating, edema, hypertension, depression, insomnia, anxiety, headache, dyspnea, fever, dizziness, rash. |
| How Supplied |
|
Tabs—30 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
